|
INDIA BUSINESS WORLD - 1st April To 15th April - 2009
CADILA LAUNCHES UNIQUE CARDIAC COMBODRUG - POLYCAP, EXPECTS RS 100 CRORE REVENUES IN 2 YRS
Ahmedabad-based Cadila Pharma has unveiled its unique cardiac combodrug—Polycap. The drug, touted as a potential blockbuster, could be the first-of-its kind by any Indian pharma company.
Giving out conservative estimates, Cadila Pharma says that the company expects to generate revenues worth Rs 100 crore from the first two years of its drug launch. The company is now open for possible marketing tie-ups with global pharma companies even as the drug would be launched in Indian market around June-July this year. The 5-in1 drug claims to reduce risk of cardiac diseases by 80%.
The company funded the research it conducted along with Dr Salim Yusuf from McMaster University, Canada, and has filed for the patent of the drug that targets people who are healthy but are prone to cardiac problems. Such a segment includes diabetics, smokers, heavy drinkers, obese, hypertensive and those with family history of cardiac problems.
Cadila Pharma that announced the drug at a crowded press conference said that the prominent feature of the drug is that it looks at tapping the non-patient segment when most of the conventional pharma companies are in a rat-race to tap cardiac patients. The company is eyeing to tap nearly 21% of non-cardiac patients in India, who are in the age group of 45 to 80 and are prone to cardiac problems due to the presence of one or the other risk factor. Globally, this age group would be quite large and Cadila is particularly eyeing regulated markets like Europe, Japan and the US.
Mr IA Modi, chairman, Cadila Pharma said: “We are open to possible marketing tie-ups with pharma companies for the global launch". Referring to the excitement in the developed world regarding the discovery of the five-in-one cardiac drug - Polycap, he said: Cadila had a presence in more than 50 countries and had already applied for the patent.
The company will soon start filing dossiers for Polycap, in different countries for getting required registration for the launch of the drug. "Domestically, we expect to get approval from Indian drug authorities in the next two to three days," he added.
The wonder drug Polycap, is a made out of five different drug constituents. There is a synergy amongst all five constituents as they satisfy the pharmacokinetics and pharmacodynamic requirements of medical standards.
|
